Modality
Gene Therapy
MOA
BTKi
Target
EGFR
Pathway
PI3K/AKT
CFMCL
Development Pipeline
Preclinical
Oct 2024
PreclinicalCurrent
NCT06558688
2,705 pts·CF
2024-10→TBD·Not yet recruiting
2,705 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q4
Preclinical
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06558688 | Preclinical | CF | Not yet recr... | 2705 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |